CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway

Apoptosis

Volumn 17, Issue 9, 2012, Pages 927-937

  Tang, Ming Rui ^a   Wang, Yu Xin ^a   Guo, Shu ^a   Han, Si Yuan ^a   Wang, Di ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; CSMD1; Melanoma; Signaling pathway; Survival rate

Indexed keywords

PROTEIN; PROTEIN CSMD1; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CSMD1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; HUMANS; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84865119738     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-012-0727-0     Document Type: Article

References (50)

1. Diffey BL (2004) The future incidence of cutaneous melanoma within the UK. Br J Dermatol 151:868-872. doi: 10.1111/j.1365-2133.2004.06216.x (Pubitemid 39482121)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90. doi: 10.3322/caac.20107
3. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20:2149-2182. doi: 10.1101/gad.1437206
4. Helmbach H, Sinha P, Schadendorf D (2003) Human melanoma: drug resistance. Recent Results Cancer Res 161:93-110
5. Li Y, Mcclay EF (2002) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29:413-426. doi: 10.1053/sonc.2002.35237 (Pubitemid 35178281)
6. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-3151. doi: 10.1038/sj.onc.1206454 (Pubitemid 36713766)
7. Beddingfield FC 3rd (2003) The melanoma epidemic: res ipsa loquitur. Oncologist 8:459-465. doi: 10.1634/theoncologist.8-5-459 (Pubitemid 37238874)
8. Grossman D, Altieri DC (2001) Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20:3-11. doi: 10.1023/A:1013123532723 (Pubitemid 34074673)
9. Agarwala SS, Kirkwood JM (1996) Interferons in melanoma. Curr Opin Oncol 8:167-174 (Pubitemid 26156443)
10. Atkins MB (2000) Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am 6:S8-S10
11. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116 (Pubitemid 29318842)
12. Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15:417-474 (Pubitemid 27224668)
13. Forozan F, Mahlamäki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, Kallioniemi OP (2000) Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 60:4519-4525 (Pubitemid 32103634)
14. Anbazhagan R, Fujii H, Gabrielson E (1998) Allelic loss of chromosomal arm 8p in breast cancer progression. Am J Pathol 152:815-819 (Pubitemid 28110728)
15. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J (2007) DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67:692-700. doi: 10.1002/pros.20543 (Pubitemid 46709438)
16. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA (2006) The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 45:31-41. doi: 10.1002/gcc.20261 (Pubitemid 46930859)
17. Zhou W, Goodman SN, Galizia G, Lieto E, Ferraraccio F, Pignatelli C, Purdie CA, Piris J, Morris R, Harrison DJ, Paty PB, Culliford A, Romans KE, Montgomery EA, Choti MA, Kinzler KW, Vogelstein B (2002) Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 359:219-225. doi: 10.1016/S0140-6736 (Pubitemid 34113820)
18. Sun PC, Uppaluri R, Schmidt AP, Pashia ME, Quant EC, Sunwoo JB, Gollin SM, Scholnick SB (2001) Transcript map of the 8p23 putative tumor suppressor region. Genomics 75:17-25. doi: 10.1006/geno.2001.6587 (Pubitemid 32607282)
19. Kirkitadze MD, Barlow PN (2001) Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 180:146-161. doi: 10.1034/j.1600-065X (Pubitemid 32472859)
20. Kamal M, Shaaban AM, Zhang L, Walker C, Gray S, Thakker N, Toomes C, Speirs V, Bell SM (2010) Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat 12:555-563. doi: 10.1007/s10549-009-0500-4
21. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS (2009) Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 8:907-916
22. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13:1303-1313. doi: 10.1093/hmg/ddh155 (Pubitemid 38961638)
23. Farrell LC, Crimm H, Meeh P, Croshaw R, Barbar T, Vandersteenhoven JJ, Butler W, Buckhaults P (2008) Somatic mutations to CSMD1 in colorectal adenocarcinomas. Cancer Biol Ther 7:609-613 (Pubitemid 351847040)
24. Wright K, Wilson PJ, Kerr J, Do K, Hurst T, Khoo SK, Ward B, Chenevix-Trench G (1998) Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene 17:1185-1188 (Pubitemid 28444604)
25. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63:4196-4203 (Pubitemid 36917946)
26. Midorikawa Y, Yamamato S, Tsuji S, Kamimura N, Ishikawa S, Igarashi H, Makuuchi M, Kokudo N, Sugimura H, Aburatani H (2008) Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology 49:513-522. doi: 10.1002/hep.22698
27. Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins G, Dai JL, Kern SE, Kinzler KW, Vogelstein B (1998) Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA 95:2412-2416 (Pubitemid 28145955)
28. Schmierer B, Hill CS (2007) TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8:970-982. doi: 10.1038/nrm2297 (Pubitemid 350174642)
29. Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL (1993) Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75:671-680. doi: 10.1016/0092-8674 (Pubitemid 23346366)
30. Lux A, Attisano L, Marchuk DA (1999) Assignment of transforming growth factor beta1 and beta 3 and a third new ligand to the type I receptor ALK-1. J Biol Chem 274:9984-9992. doi: 10.1074/jbc.274.15.9984 (Pubitemid 29180861)
31. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23:4018-4028. doi: 10.1038/sj.emboj.7600386 (Pubitemid 39472423)
32. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P (2003) Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12:817-828. doi: 10.1016/S1097-2765 (Pubitemid 37352776)
33. Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S, Marini FC 3rd, Fang B (2004) Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 10:3535-3541. doi: 10.1158/1078-0432 (Pubitemid 38685464)
34. Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, Chiao P, Fang B (2004) Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 9:666-673. doi: 10.1016/j.ymthe.2004.02.007 (Pubitemid 38660419)
35. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE (1996) Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56:490-494 (Pubitemid 26043644)
36. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE (1998) Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58:5329-5332 (Pubitemid 28551110)
37. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13:343-346. doi: 10.1038/ng0796-343 (Pubitemid 26230501)
38. Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Costantini R, Gulino A, Coppa A (2005) A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene 24:5344-5354. doi: 10.1038/sj.onc.1208603 (Pubitemid 43080104)
39. Okano H, Shinohara H, Miyamoto A, Takaori K, Tanigawa N (2004) Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome. Clin Cancer Res 10:6938-6945. doi: 10.1158/1078-0432 (Pubitemid 39383044)
40. Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM, Gullino PM (1987) Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 47:4243-4247 (Pubitemid 17124310)
41. Ivkovic-Kapic T, Knelevic-Usaj S, Panjkovic M, Mastilovic K (2006) Immunohistochemical analysis of angiogenesis in invasive ductal breast carcinoma with correlations to clinicopathological factor. Vojnosanit Pregl 63:635-642
42. Bockmuhl U, Ishwad CS, Ferrell RE, Gollin SM (2001) Association of 8p23 deletions with poor survival in head and neck cancer. Otolaryngol Head Neck Surg 124:451-455. doi: 10.1067/mhn.2001.114794 (Pubitemid 33587110)
43. Kerbel RS (1997) A cancer therapy resistant to resistance. Nature 390:335-336. doi: 10.1038/36978 (Pubitemid 28027292)
44. Washburn JG, Wojno KJ, Dey J, Powell IJ, Macoska JA (2000) 8pter-p23 deletion is associated with racial differences in prostate cancer outcome. Clin Cancer Res 6:4647-4652 (Pubitemid 32110400)
45. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE (1996) Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148(6):1887-1894
46. Krasagakis K, Thölke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77(9):1492-1494 (Pubitemid 28190751)
47. Heldin CH, Landström M, Moustakas A (2009) Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 21(2):166-176. doi: 10.1016/j.ceb.2009.01.021
48. Grau AM, Zhang L, Wang W, Ruan S, Evans DB, Abbruzzese JL, Zhang W, Chiao PJ (1997) Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 57(18):3929-3934 (Pubitemid 27427678)
49. Guo Y, Kyprianou N (1998) Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 9(2):185-193 (Pubitemid 128472559)
50. Wendt MK, Smith JA, Schiemann WP (2009) p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem 284:34145-34156. doi: 10.1074/jbc.M109.023614